HistoSonics, a Minneapolis, MN-based producer of the Edison® Histotripsy System and novel histotripsy remedy platforms, closed $102m Sequence D financing.
The spherical was led by Alpha Wave Ventures, with participation from new traders Amzak Well being and HealthQuest Capital, and current traders Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Enterprise Traders, Lumira Ventures, Yonjin Enterprise, the State of Wisconsin Funding Board, and others.
Led by Mike Blue, President & CEO, HistoSonics is a medical system firm growing non-invasive platforms and proprietary sonic beam remedy using the science of histotripsy, a novel mechanism of motion that makes use of centered ultrasound to mechanically destroy and liquify undesirable tissue and tumors. The corporate is at present centered on commercializing their Edison System within the US and choose international markets for liver remedy whereas increasing histotripsy functions into different organs like kidney, pancreas, prostate, mind, and others. HistoSonics has places of work in Ann Arbor, Michigan, and Minneapolis, Minnesota. The Edison® System is meant for the non-invasive mechanical destruction of liver tumors, together with the partial or full destruction of unresectable liver tumors by way of histotripsy. The FDA has not evaluated the Edison System for the remedy of any particular illness or situation.
The Sequence D funding will likely be used to speed up developments to its non-invasive histotripsy platforms, help business development within the US and in deliberate international markets, and provoke the corporate’s modern, potential BOOMBOX Grasp Research that can consider HistoSonics’ Edison System for the remedy of liver tumors throughout multidisciplinary customers. The Edison Histotripsy System was granted FDA De Novo clearance in October 2023. HistoSonics is at present partnering with main establishments throughout the US and internationally in growing multi-disciplinary histotripsy liver packages.
FinSMEs
15/08/2024
